Physician

Faisal Musa, MD

According to 2025 Medicare claims, Faisal Musa, MD (NPI: 1811138787) practices hematology/oncology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is MICHIGAN HEALTHCARE PROFESSIONALS PC (NPI: 1295023547; TIN: 451674932) and primary practice location at 48126-9998. Musa is affiliated with the Arvon CIN (ACO ID: A1095) and Honest ACO of Michigan LLC (ACO ID: D0236), participating under both the MSSP and REACH models.

Musa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 830 traditional Medicare patients, billed 351,759 HCPCS/CPT codes, and received $5,373,284 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 6,166 prescription claims across 864 beneficiaries totaling $14,759,014 in drug costs, led by Xtandi (Enzalutamide). DME data shows 98 claims. Open Payments data shows 336 records totaling $405,521. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $42,446 to $5,373,284. Similarly, Part D prescription costs have moved sharply higher in recent years, from $26,227 to $14,759,014. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	154	638	$42,446
2017	564	2,687	$211,405
2018	723	3,038	$265,620
2019	896	3,328	$260,598
2020	976	3,269	$277,485
2021	1,028	27,443	$662,571
2022	1,005	173,942	$3,888,842
2023	910	247,241	$5,073,942
2024	830	351,759	$5,373,284

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	62	117	$26,227
2016	66	151	$31,188
2017	183	1,084	$822,709
2018	343	1,960	$2,005,995
2019	444	2,770	$2,686,970
2020	519	2,986	$3,788,523
2021	584	4,000	$5,787,299
2022	670	4,558	$6,323,866
2023	771	5,344	$9,351,144
2024	864	6,166	$14,759,014

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	40	$11,038
2018	N/R	17	$151
2019	N/R	43	$5,839
2020	N/R	65	$5,572
2021	N/R	32	$2,322
2022	N/R	130	$66,038
2023	22	106	$8,001
2024	22	98	$2,664

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	162	180	$137
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	504	1,287	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	159	199	$64
96372	Injection of drug or substance under skin or into muscle	162	645	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	523	1,709	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	123	3,670	$1,637,253
Jakafi	Ruxolitinib Phosphate	85	2,550	$1,379,355
Verzenio	Abemaciclib	58	1,624	$852,844
Pomalyst	Pomalidomide	36	1,008	$794,723
Lenvima	Lenvatinib Mesylate	35	1,050	$729,273

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	11	46	$1,949
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	34	$414
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	18	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	332	$227,580	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$177,941	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Faisal Musa, MD?

Tedicare shows public-source Medicare data for Faisal Musa, MD (NPI 1811138787), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Faisal Musa, MD have ACO affiliation data?

Faisal Musa, MD is shown with ACO affiliation data for Arvon CIN (MSSP, ACO ID A1095) and Honest ACO of Michigan LLC (REACH, ACO ID D0236).

What billing organization is linked to Faisal Musa, MD?

Faisal Musa, MD is linked to MICHIGAN HEALTHCARE PROFESSIONALS PC (billing NPI 1295023547) in the available physician profile data.

Does Faisal Musa, MD have Open Payments data?

Faisal Musa, MD has 336 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.